B Cell News and Research

RSS

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally advanced non-small cell lung cancer without chemotherapy met its primary endpoint with tolerable adverse reactions.

8 Aug 2022

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free survival compared with historical controls despite a shortened interval (6 months) of treatment.

8 Aug 2022

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small cell lung cancer.

8 Aug 2022

Researchers identify immune expression signature in surgical specimens linked to disease progression for non-CPR patients

Researchers from Spain have identified an immune expression signature in surgical specimens associated with disease progression for non-complete pathological responders patients treated with neo adjuvant chemo-immunotherapy, which could help the follow-up and therapeutic management of these high-risk patients.

8 Aug 2022

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to findings presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Study reveals the intertumoral heterogeneity of METex14 skipping positive NSCLCs

A study presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinical-relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping.

8 Aug 2022

Study compares the nodule management protocols used in NELSON and National Lung Cancer Screening Trial

The protocol used to screen and detect lung cancer in the NELSON Trial is more sensitive than the protocol used in the National Lung Cancer Screening Trial, particularly for early-stage cancers, according to research reported today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Research highlights the need to increase early detection of lung cancer among younger patients

Younger patients with lung cancer are significantly more likely than older patients to be diagnosed with later stages of disease, illustrating the need to develop strategies to increase the early detection of lung cancer among younger patients who are currently ineligible for lung cancer screening.

8 Aug 2022

Sub lobar surgery found to be non-inferior to lobectomy for patients with small-sized peripheral NSCLC

A large international study of patients with non-small cell lung cancer tumors that are two centimeters or less found that sub lobar surgery was non-inferior to lobectomy, according to results presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Increased use of stereotactic body radiation therapy for NSCLC patients can reduce treatment disparities

The use of Stereotactic Body Radiotherapy (SBRT) for patients with non-small cell lung cancer can reduce treatment disparities between White and Black patients, according to research presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Researchers examine the incidence of second primary lung cancers using National Lung Screening Trial data

Using data from the National Lung Screening Trial, researchers found that the incidence of second primary lung cancer was approximately 4% among the entire cohort of lung cancer patients and was as high as 8% among patients undergoing surgery for stage IA disease.

8 Aug 2022

Researchers unravel the mechanism of teixobactin at the atomic level

Researchers explored the mechanisms underlying the bactericidal action of teixobactin at an atomic level.

8 Aug 2022

Scientists find key molecular differences between breast cancer cells in initial and metastatic tumors

Studying a deadly type of breast cancer called triple negative, Johns Hopkins Medicine scientists say they have identified key molecular differences between cancer cells that cling to an initial tumor and those that venture off to form distant tumors.

8 Aug 2022

B Cell News and Research

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Researchers identify immune expression signature in surgical specimens linked to disease progression for non-CPR patients

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

Study reveals the intertumoral heterogeneity of METex14 skipping positive NSCLCs

Study compares the nodule management protocols used in NELSON and National Lung Cancer Screening Trial

Research highlights the need to increase early detection of lung cancer among younger patients

Sub lobar surgery found to be non-inferior to lobectomy for patients with small-sized peripheral NSCLC

Increased use of stereotactic body radiation therapy for NSCLC patients can reduce treatment disparities

Researchers examine the incidence of second primary lung cancers using National Lung Screening Trial data

Researchers unravel the mechanism of teixobactin at the atomic level

Scientists find key molecular differences between breast cancer cells in initial and metastatic tumors

Inhaled aprotinin found to reduce viral load in mild-to-moderate COVID-19

Research progress on the three-dimensional interaction between virus and host genome

What is the impact of SARS-CoV-2 Omicron BA.2 breakthrough infection on novel Omicron sublineages?

Researchers identify new therapies that could provide better protection against future COVID-19 variants

Human intestine-on-a-chip for modeling intestinal injury associated with a pediatric inflammatory disorder

Sustainable Science; What does the future look like?

Assessing immunization capacity of vaccine platforms with DNA origami harboring SARS-CoV-2 receptor binding domain

Immunology eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News